Samuel Agresta - 11 Sep 2023 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)

Role
Chief Medical Officer
Signature
/s /Allan Reine, M.D., Attorney-in-Fact
Issuer symbol
FHTX
Transactions as of
11 Sep 2023
Net transactions value
$0
Form type
4
Filing time
13 Sep 2023, 16:02:28 UTC
Previous filing
18 Aug 2023
Next filing
08 Oct 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding FHTX Stock Options (Right to buy) 100,000 11 Sep 2023 Common Stock 100,000 $16.63 Direct F1
holding FHTX Stock Options (Right to buy) 125,000 11 Sep 2023 Common Stock 125,000 $14.87 Direct F2
holding FHTX Stock Options (Right to buy) 91,891 11 Sep 2023 Common Stock 91,891 $8.77 Direct F3
holding FHTX Stock Options (Right to buy) 60,000 11 Sep 2023 Common Stock 60,000 $8.38 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Samuel Agresta is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter.
F2 The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter.
F3 The option vested as to 25% of the underlying shares of common stock on August 17, 2021, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter.
F4 The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.

Remarks:

Exit Form 4 filed solely to report the Reporting Person is no longer an officer of the Issuer within the meaning of Rule 16a-1 of the Securities Exchange Act of 1934, as amended.